The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
Its DirectDetect reagent eliminates RNA extraction for rapid deployment of Covid-19 tests in affected countries
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
Eka Care will provide a six-month complimentary trial period to all members who register before December 31, 2021
Study to explore heterologous regimen of COVID-19 vaccines from different manufacturers in adolescents 12-16 years of age
Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
The first lot of IPV will be supplied to the government this month as per the requirement of the Health Ministry
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
Subscribe To Our Newsletter & Stay Updated
